Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated May 14, 2026, serves as a transaction notification for the month of May 2026. The document discloses share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific equity transactions.
- Instrument: Ordinary shares of 31 1/2 pence each (ISIN: GB00BN7SWP63).
- Transaction Price: £18.6559 per share.
- Transaction Date: May 12, 2026.
- Exchange: London Stock Exchange (XLON).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely records routine share acquisitions by senior executives and their associates.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity.
Important Facts for Investors
- Executive Participation: Eight individuals, including the CFO (Julie Brown), CEO of ViiV Healthcare (Deborah Waterhouse), and President of Europe (Lynn Baxter), acquired shares.
- Transaction Volume: Total acquisitions ranged from 12 to 14 shares per individual, consisting of partnership and matching shares.
- Market Price: The transactions occurred at a uniform price of £18.6559.
- Plan Type: All acquisitions were made under the Company's Share Reward Plan, indicating standard compensation-related activity rather than open-market speculation.